1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Feline	_	_	NN	_	_	_	_	_
2	leukaemia	_	_	NN	_	_	_	_	_
3	virus	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	FeLV	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	gammaretrovirus	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	infects	_	_	VBZ	_	_	_	_	_
12	domestic	_	_	JJ	_	_	_	_	_
13	cats	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	closely	_	_	RB	_	_	_	_	_
16	related	_	_	VBN	_	_	_	_	_
17	wild	_	_	JJ	_	_	_	_	_
18	felids	_	_	NNS	_	_	_	_	_
19	worldwide	_	_	RB	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	first	_	_	JJ	_	_	_	_	_
4	description	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	virus	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	1964	_	_	CD	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	feline	_	_	JJ	_	_	_	_	_
12	lymphoma	_	_	NN	_	_	_	_	_
13	tissue	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	increasing	_	_	VBG	_	_	_	_	_
16	knowledge	_	_	NN	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	gained	_	_	VBN	_	_	_	_	_
20	concerning	_	_	VBG	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	pathogenesis	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	diagnosis	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	treatment	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	infection	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	FeLV	_	_	NN	_	_	_	_	_
2	infection	_	_	NN	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	lead	_	_	VB	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	fatal	_	_	JJ	_	_	_	_	_
7	diseases	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	cats	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	progressive	_	_	JJ	_	_	_	_	_
12	infection	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Testing	_	_	VBG	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	eradication	_	_	NN	_	_	_	_	_
4	programs	_	_	NNS	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	introduction	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	effective	_	_	JJ	_	_	_	_	_
10	vaccines	_	_	NNS	_	_	_	_	_
11	led	_	_	VBD	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	decrease	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	FeLV	_	_	NN	_	_	_	_	_
17	prevalence	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	many	_	_	JJ	_	_	_	_	_
20	countries	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	last	_	_	JJ	_	_	_	_	_
24	30	_	_	CD	_	_	_	_	_
25	years	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	more	_	_	RBR	_	_	_	_	_
4	recently	_	_	RB	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	decrease	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	FeLV	_	_	NN	_	_	_	_	_
11	prevalence	_	_	NN	_	_	_	_	_
12	has	_	_	VBZ	_	_	_	_	_
13	stagnated	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	other	_	_	JJ	_	_	_	_	_
3	countries	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	such	_	_	JJ	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	Denmark	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	FeLV	_	_	NNP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	rarely	_	_	RB	_	_	_	_	_
12	detected	_	_	VBN	_	_	_	_	_
13	nowadays	_	_	RB	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	USA	_	_	NNP	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Canada	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	Australia	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	large	_	_	JJ	_	_	_	_	_
11	prevalence	_	_	NN	_	_	_	_	_
12	studies	_	_	NNS	_	_	_	_	_
13	have	_	_	VBP	_	_	_	_	_
14	been	_	_	VBN	_	_	_	_	_
15	published	_	_	VBN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	some	_	_	DT	_	_	_	_	_
6	recent	_	_	JJ	_	_	_	_	_
7	studies	_	_	NNS	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	prevalence	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	FeLV	_	_	NNP	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	single	_	_	JJ	_	_	_	_	_
15	European	_	_	JJ	_	_	_	_	_
16	countries	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	no	_	_	DT	_	_	_	_	_
7	pan-European	_	_	JJ	_	_	_	_	_
8	study	_	_	NN	_	_	_	_	_
9	determining	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	current	_	_	JJ	_	_	_	_	_
12	FeLV	_	_	NN	_	_	_	_	_
13	prevalence	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	domestic	_	_	JJ	_	_	_	_	_
16	cats	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	FeLV	_	_	NN	_	_	_	_	_
2	prevalence	_	_	NN	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	vary	_	_	VB	_	_	_	_	_
5	considerably	_	_	RB	_	_	_	_	_
6	depending	_	_	VBG	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	composition	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	investigated	_	_	VBN	_	_	_	_	_
13	cat	_	_	NN	_	_	_	_	_
14	population	_	_	NN	_	_	_	_	_
15	;	_	_	:	_	_	_	_	_
16	feral	_	_	JJ	_	_	_	_	_
17	or	_	_	CC	_	_	_	_	_
18	stray	_	_	JJ	_	_	_	_	_
19	cats	_	_	NNS	_	_	_	_	_
20	versus	_	_	CC	_	_	_	_	_
21	privately	_	_	RB	_	_	_	_	_
22	owned	_	_	VBN	_	_	_	_	_
23	cats	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	cats	_	_	NNS	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	shelters	_	_	NNS	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	from	_	_	IN	_	_	_	_	_
30	breeders	_	_	NNS	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	clinically	_	_	RB	_	_	_	_	_
33	healthy	_	_	JJ	_	_	_	_	_
34	cats	_	_	NNS	_	_	_	_	_
35	or	_	_	CC	_	_	_	_	_
36	sick	_	_	JJ	_	_	_	_	_
37	cats	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	preselection	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	samples	_	_	NNS	_	_	_	_	_
8	has	_	_	VBZ	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	influence	_	_	NN	_	_	_	_	_
11	;	_	_	:	_	_	_	_	_
12	e.	_	_	FW	_	_	_	_	_
13	g.	_	_	FW	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	if	_	_	IN	_	_	_	_	_
16	samples	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	obtained	_	_	VBN	_	_	_	_	_
19	only	_	_	RB	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	cats	_	_	NNS	_	_	_	_	_
22	suspected	_	_	VBN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	being	_	_	VBG	_	_	_	_	_
25	infected	_	_	VBN	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	FeLV	_	_	NNP	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	recent	_	_	JJ	_	_	_	_	_
3	meta-analysis	_	_	NN	_	_	_	_	_
4	suggested	_	_	VBD	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	indirect	_	_	JJ	_	_	_	_	_
7	relation	_	_	NN	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	FeLV	_	_	NN	_	_	_	_	_
10	prevalence	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	yearly	_	_	JJ	_	_	_	_	_
14	gross	_	_	JJ	_	_	_	_	_
15	domestic	_	_	JJ	_	_	_	_	_
16	product	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	GDP	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	per	_	_	IN	_	_	_	_	_
21	capita	_	_	NN	_	_	_	_	_
22	using	_	_	VBG	_	_	_	_	_
23	purchasing	_	_	VBG	_	_	_	_	_
24	power	_	_	NN	_	_	_	_	_
25	parity	_	_	NN	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	PPP	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	i.	_	_	FW	_	_	_	_	_
31	e.	_	_	FW	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	total	_	_	JJ	_	_	_	_	_
35	value	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	all	_	_	PDT	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	goods	_	_	NNS	_	_	_	_	_
40	and	_	_	CC	_	_	_	_	_
41	services	_	_	NNS	_	_	_	_	_
42	produced	_	_	VBN	_	_	_	_	_
43	by	_	_	IN	_	_	_	_	_
44	a	_	_	DT	_	_	_	_	_
45	country	_	_	NN	_	_	_	_	_
46	in	_	_	IN	_	_	_	_	_
47	a	_	_	DT	_	_	_	_	_
48	particular	_	_	JJ	_	_	_	_	_
49	year	_	_	NN	_	_	_	_	_
50	,	_	_	,	_	_	_	_	_
51	divided	_	_	VBN	_	_	_	_	_
52	by	_	_	IN	_	_	_	_	_
53	the	_	_	DT	_	_	_	_	_
54	number	_	_	NN	_	_	_	_	_
55	of	_	_	IN	_	_	_	_	_
56	people	_	_	NNS	_	_	_	_	_
57	living	_	_	VBG	_	_	_	_	_
58	there	_	_	RB	_	_	_	_	_
59	and	_	_	CC	_	_	_	_	_
60	corrected	_	_	VBN	_	_	_	_	_
61	for	_	_	IN	_	_	_	_	_
62	purchasing	_	_	VBG	_	_	_	_	_
63	power	_	_	NN	_	_	_	_	_
64	using	_	_	VBG	_	_	_	_	_
65	a	_	_	DT	_	_	_	_	_
66	“	_	_	``	_	_	_	_	_
67	basket	_	_	NN	_	_	_	_	_
68	of	_	_	IN	_	_	_	_	_
69	goods	_	_	NNS	_	_	_	_	_
70	”	_	_	''	_	_	_	_	_
71	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	FeLV	_	_	NNP	_	_	_	_	_
5	prevalence	_	_	NN	_	_	_	_	_
6	data	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	available	_	_	JJ	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	many	_	_	JJ	_	_	_	_	_
11	European	_	_	JJ	_	_	_	_	_
12	countries	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	data	_	_	NNS	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	obtained	_	_	VBN	_	_	_	_	_
19	several	_	_	JJ	_	_	_	_	_
20	years	_	_	NNS	_	_	_	_	_
21	ago	_	_	RB	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	present	_	_	JJ	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	determine	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	current	_	_	JJ	_	_	_	_	_
12	prevalence	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	FeLV	_	_	NN	_	_	_	_	_
15	viraemia	_	_	NN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	cats	_	_	NNS	_	_	_	_	_
18	that	_	_	WDT	_	_	_	_	_
19	visit	_	_	VBP	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	veterinary	_	_	JJ	_	_	_	_	_
22	facility	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	protocol	_	_	NN	_	_	_	_	_
4	included	_	_	VBD	_	_	_	_	_
5	cats	_	_	NNS	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	32	_	_	CD	_	_	_	_	_
8	European	_	_	JJ	_	_	_	_	_
9	countries	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	survey	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	order	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	avoid	_	_	VB	_	_	_	_	_
5	any	_	_	DT	_	_	_	_	_
6	preselection	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	cats	_	_	NNS	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	apart	_	_	RB	_	_	_	_	_
12	from	_	_	IN	_	_	_	_	_
13	visiting	_	_	VBG	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	veterinary	_	_	JJ	_	_	_	_	_
16	facility	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	10	_	_	CD	_	_	_	_	_
20	animals	_	_	NNS	_	_	_	_	_
21	arriving	_	_	VBG	_	_	_	_	_
22	consecutively	_	_	RB	_	_	_	_	_
23	at	_	_	IN	_	_	_	_	_
24	each	_	_	DT	_	_	_	_	_
25	facility	_	_	NN	_	_	_	_	_
26	were	_	_	VBD	_	_	_	_	_
27	tested	_	_	VBN	_	_	_	_	_
28	independently	_	_	RB	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	reason	_	_	NN	_	_	_	_	_
32	for	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	veterinary	_	_	JJ	_	_	_	_	_
35	appointment	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Risk	_	_	NN	_	_	_	_	_
2	and	_	_	CC	_	_	_	_	_
3	protective	_	_	JJ	_	_	_	_	_
4	factors	_	_	NNS	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	FeLV	_	_	NN	_	_	_	_	_
7	infection	_	_	NN	_	_	_	_	_
8	were	_	_	VBD	_	_	_	_	_
9	determined	_	_	VBN	_	_	_	_	_
10	using	_	_	VBG	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	demographic	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	husbandry	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	as	_	_	RB	_	_	_	_	_
18	well	_	_	RB	_	_	_	_	_
19	as	_	_	IN	_	_	_	_	_
20	FeLV	_	_	NN	_	_	_	_	_
21	vaccination	_	_	NN	_	_	_	_	_
22	history	_	_	NN	_	_	_	_	_
23	data	_	_	NNS	_	_	_	_	_
24	from	_	_	IN	_	_	_	_	_
25	each	_	_	DT	_	_	_	_	_
26	cat	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	using	_	_	VBG	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	data	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	we	_	_	PRP	_	_	_	_	_
8	tested	_	_	VBD	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	recently	_	_	RB	_	_	_	_	_
11	postulated	_	_	VBN	_	_	_	_	_
12	hypothesis	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	correlation	_	_	NN	_	_	_	_	_
16	between	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	FeLV	_	_	NN	_	_	_	_	_
19	prevalence	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	GDP	_	_	NN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	European	_	_	JJ	_	_	_	_	_
25	countries	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	extended	_	_	VBD	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	analysis	_	_	NN	_	_	_	_	_
31	to	_	_	TO	_	_	_	_	_
32	test	_	_	VB	_	_	_	_	_
33	also	_	_	RB	_	_	_	_	_
34	for	_	_	IN	_	_	_	_	_
35	a	_	_	DT	_	_	_	_	_
36	potential	_	_	JJ	_	_	_	_	_
37	correlation	_	_	NN	_	_	_	_	_
38	with	_	_	IN	_	_	_	_	_
39	FeLV	_	_	NN	_	_	_	_	_
40	vaccination	_	_	NN	_	_	_	_	_
41	rates	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	minimally	_	_	RB	_	_	_	_	_
3	invasive	_	_	JJ	_	_	_	_	_
4	sample	_	_	NN	_	_	_	_	_
5	collection	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	avoid	_	_	VB	_	_	_	_	_
9	bias	_	_	NN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	requesting	_	_	VBG	_	_	_	_	_
12	blood	_	_	NN	_	_	_	_	_
13	collection	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	saliva	_	_	NN	_	_	_	_	_
16	swabs	_	_	NNS	_	_	_	_	_
17	were	_	_	VBD	_	_	_	_	_
18	collected	_	_	VBN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	analysed	_	_	VBN	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	RT-qPCR	_	_	NNP	_	_	_	_	_
23	;	_	_	:	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	detection	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	viral	_	_	JJ	_	_	_	_	_
28	RNA	_	_	NN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	RT-qPCR	_	_	NNP	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	saliva	_	_	NN	_	_	_	_	_
33	was	_	_	VBD	_	_	_	_	_
34	shown	_	_	VBN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	be	_	_	VB	_	_	_	_	_
37	an	_	_	DT	_	_	_	_	_
38	excellent	_	_	JJ	_	_	_	_	_
39	measure	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	FeLV	_	_	NN	_	_	_	_	_
42	viraemia	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_

